A Simulation Study Comparing Different Statistical Approaches for the Identification of Predictive Biomarkers
暂无分享,去创建一个
[1] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[2] Willi Sauerbrei,et al. Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis , 2014, Statistics in medicine.
[3] Thomas M. Loughin,et al. A residual bootstrap for regression parameters in proportional hazards models , 1995 .
[4] James J. Chen,et al. Predictive biomarkers for treatment selection: statistical considerations. , 2015, Biomarkers in medicine.
[5] W. Hacke,et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial , 2006, The Lancet.
[6] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .
[7] W. Sauerbrei,et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.
[8] P. Royston,et al. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials , 2004, Statistics in medicine.
[9] Kristopher J Preacher,et al. On the practice of dichotomization of quantitative variables. , 2002, Psychological methods.
[10] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[11] Matthew J. Selleck,et al. Making Meaningful Clinical Use of Biomarkers , 2017, Biomarker insights.
[12] Katherine Karakasis,et al. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. , 2015, The Lancet. Oncology.
[13] Glen Reid,et al. An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer , 2018, Journal of clinical medicine.
[14] P. Royston,et al. Interactions between treatment and continuous covariates: a step toward individualizing therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Marco Bonetti,et al. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP , 2016, Clinical trials.
[16] I. Lipkovich,et al. Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials , 2017, Statistics in medicine.
[17] Bingshu E. Chen,et al. Testing for treatment‐biomarker interaction based on local partial‐likelihood , 2015, Statistics in medicine.
[18] Michael den Bakker,et al. Prognostic and predictive biomarkers in lung cancer. A review , 2014, Virchows Archiv.
[19] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Kenneth P.H. Pritzker,et al. Predictive and prognostic cancer biomarkers revisited , 2015, Expert review of molecular diagnostics.
[21] W. Hacke,et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial , 2008, The Lancet Neurology.
[22] Richard D Riley,et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research , 2013, BMJ : British Medical Journal.
[23] A. Dreher. Modeling Survival Data Extending The Cox Model , 2016 .
[24] M. Bonetti,et al. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. , 2000, Statistics in medicine.
[25] Anne-Laure Boulesteix,et al. A Plea for Neutral Comparison Studies in Computational Sciences , 2012, PloS one.
[26] B. Freidlin,et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. , 2013, Journal of the National Cancer Institute.
[27] Xin Victoria Wang,et al. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes , 2016, Clinical trials.
[28] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[29] K. Strimbu,et al. What are biomarkers? , 2010, Current opinion in HIV and AIDS.
[30] D.,et al. Regression Models and Life-Tables , 2022 .
[31] D. Altman,et al. Analysis by Categorizing or Dichotomizing Continuous Variables Is Inadvisable: An Example from the Natural History of Unruptured Aneurysms , 2011, American Journal of Neuroradiology.
[32] Katherine Karakasis,et al. Outcomes and endpoints in cancer trials: bridging the divide. , 2015, The Lancet. Oncology.
[33] Patrick Royston,et al. Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis , 2013, Statistics in medicine.
[34] P. Royston,et al. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. , 1994 .
[35] Marco Bonetti,et al. Another STEPP in the right direction. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Melanie Boerries,et al. Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience , 2018, JCO precision oncology.
[37] Jacob Cohen. The Cost of Dichotomization , 1983 .
[38] T. Friede,et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[39] Patrick Royston,et al. Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials , 2009 .
[40] Werner Vach,et al. Regression Models as a Tool in Medical Research , 2012 .
[41] Lu Tian,et al. A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.
[42] W. Robinson,et al. Biomarkers to guide clinical therapeutics in rheumatology? , 2016, Current opinion in rheumatology.
[43] W. Hacke,et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial , 2006, The Lancet.
[44] Jianqing Fan,et al. Local partial-likelihood estimation for lifetime data , 2006, math/0605511.
[45] N S El Saghir,et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] Kurt Ulm,et al. Investigation of age–treatment interaction in the SPACE trial using different statistical approaches , 2019, Journal of Applied Statistics.
[47] E. Rutgers,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] Patrick Royston,et al. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .
[49] P Baas,et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] Marco Bonetti,et al. A small sample study of the STEPP approach to assessing treatment–covariate interactions in survival data , 2009, Statistics in medicine.